Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

GLP-1 Receptor Agonist (Trulicity, Wegovy, Ozempic, Mounjaro) Market Trends Analysis Report 2026

globenewswire.com
LLY Eli Lilly's Trulicity is mentioned as a benchmark in a trial where a competitor's drug showed superiority in glycemic control and cardiometabolic benefits, including weight loss. However, Eli Lilly is also listed as a developer of new GLP-1 drugs, indicating ongoing involvement and potential future growth in the market. NVO Novo Nordisk announced a significant investment of approximately USD 2.32 billion in developing GLP-1 drugs. This substantial financial commitment signals strong confidence in the growth and future potential of this market segment for the company.

GLP-1 Receptor Agonist (Trulicity, Wegovy, Ozempic, Mounjaro) Market Trends Analysis Report 2026 Dublin, March 05, 2026 (GLOBE NEWSWIRE) -- The "GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report by Product (Trulicity, Wegovy, Ozempic, Mounjaro), Application (Diabetes, Obesity), Route of Administration, and Region with Growth Forecasts, 2026-2033" report has been added to ResearchAndMarkets.com's offering.

The global GLP-1 receptor agonist market size was estimated at USD 70.08 billion in 2025 and is projected to reach USD 201.79 billion by 2033, growing at a CAGR of 12.78% from 2026 to 2033.

The launch of new glucagon-like peptide 1 (GLP-1) receptor agonist products, a robust product pipeline for both diabetes & obesity applications, and the high efficacy of these drugs are anticipated to propel market growth.

In May 2024, Innovent Biologics announced that its type 2 diabetes candidate, mazdutide, outperformed Eli Lilly's Trulicity (dulaglutide) in a Phase III trial. The study established that mazdutide was superior in glycemic control and provided numerous cardiometabolic benefits, comprising weight loss & improvements in blood lipid levels, liver enzymes, serum uric acid, & blood pressure.

Other companies, such as Boehringer Ingelheim International GmbH, Carmot Therapeutics, Inc., D&D Pharmatech, Eli Lilly and Company (Lilly), and Hanmi Pharm. Co., Ltd, are also involved in developing new glucagon-like peptide 1 drugs. For instance, in October 2023, Carmot Therapeutics, Inc. published preliminary results from the single ascending dose (SAD) phase of an ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) that is presently being assessed in a first-in-human clinical trial in individuals who are overweight or obese. Thus, increasing research in the field of GLP-1 receptor agonists is expected to drive market growth.

Moreover, the rising prevalence of obesity and diabetes is expected to drive the growth of the GLP-1 receptor agonist industry. The overweight and obese population is at a high risk of developing diabetes and cardiovascular illness. Worldwide obesity rates are rising, and it is widely acknowledged that this is one of the major public health issues of the present day.

According to the World Heart Federation's global estimate, almost 2.3 billion children and adults worldwide suffer from obesity and overweight. Additionally, according to the Obesity Action Coalition (OAC), over 90% of individuals diagnosed with type 2 diabetes are either overweight or have some degree of obesity. Therefore, the rising obese and diabetes populations are driving the demand for GLP-1 receptor agonist drugs for treatment worldwide.

The high advantages associated with the use of GLP-1 drugs over other medicines, along with increasing investment in the R&D of new GLP-1 drugs, are driving market growth. Several GLP agonists have been linked to weight loss or weight neutrality, which is advantageous for people with diabetes since obesity frequently makes the disease worse.

The lowering of appetite and the delayed stomach emptying contribute to the weight loss effect. Moreover, in November 2023, Novo Nordisk announced its intention to invest approximately 16 billion Danish kroner in developing GLP-1 drugs. This is roughly equivalent to USD 2.32 billion (€2.14 billion). These initiatives are anticipated to drive the market's growth.

Why You Should Buy This Report

This report addresses:

Key Attributes:

Market Dynamics

Market driver analysis

Market restraint analysis

GLP-1 Receptor Agonist Market Analysis Tools

Companies Featured

Global GLP-1 Receptor Agonist Market Report Segmentation

Product Outlook (Revenue, USD Million, 2021-2033)

Application Outlook (Revenue, USD Million, 2021-2033)

Route of administration Outlook (Revenue, USD Million, 2021-2033)

Distribution Channel Outlook (Revenue, USD Million, 2021-2033)

Regional Outlook (Revenue, USD Million, 2021-2033)

For more information about this report visit https://www.researchandmarkets.com/r/9il4yp

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment